Log in

Relevant bibliographies by topics / Antineoplastic agents: pharmacology. Cancer / Journal articles

To see the other types of publications on this topic, follow the link: Antineoplastic agents: pharmacology. Cancer.

Journal articles on the topic 'Antineoplastic agents: pharmacology. Cancer'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antineoplastic agents: pharmacology. Cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Lichtman, Stuart M., J. Andrew Skirvin, and Sunitha Vemulapalli. "Pharmacology of antineoplastic agents in older cancer patients." Critical Reviews in Oncology/Hematology 46, no. 2 (2003): 101–14. http://dx.doi.org/10.1016/s1040-8428(02)00120-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Melamed, Andra J., and Michael L. Kleinberg. "Handling Considerations for Cancer Chemotherapeutic Agents." Drug Intelligence & Clinical Pharmacy 22, no. 3 (1988): 247–51. http://dx.doi.org/10.1177/106002808802200317.

Full text

Abstract:

Since the introduction of antineoplastic agents in the 1940s, there have been reports of the effects of these agents on workers who have had prolonged contact with them. The Regional Oncology Drug Information Center (RODIC) at Memorial Sloan-Kettering Cancer Center receives numerous inquiries nationwide regarding our policies and procedures for handling antineoplastic agents. In August 1987, RODIC conducted a computerized literature search on the handling of antineoplastic agents and the risks to hospital employees coming in contact with these agents. We used the MEDLINE system from 1966 to th

APA, Harvard, Vancouver, ISO, and other styles

3

Garcia, Gwenalyn, and Jean Paul Atallah. "Antineoplastic agents and thrombotic microangiopathy." Journal of Oncology Pharmacy Practice 23, no. 2 (2016): 135–42. http://dx.doi.org/10.1177/1078155216628324.

Full text

Abstract:

Thrombotic microangiopathy is an uncommon but reported adverse effect of a variety of antineoplastic drugs, including chemotherapy agents such as mitomycin C and gemcitabine, and newer targeted agents such as the vascular endothelial growth factor inhibitors. We present a review of thrombotic microangiopathy associated with antineoplastic agents and its implications in current cancer therapy.

APA, Harvard, Vancouver, ISO, and other styles

4

Fortner, Clarence L., and Paul J. Vilk. "Aspects of Investigational Antineoplastic Agents." Journal of Pharmacy Practice 4, no. 1 (1991): 64–71. http://dx.doi.org/10.1177/089719009100400107.

Full text

Abstract:

Investigational drugs are regulated by the Food and Drug Administration (FDA) and are not available for widespread patient use. They are screened and evaluated extensively before they are administered to humans in clinical trials. The clinical development process is divided into three phases: phase I, II, and III. Protocols for the investigational agent in each of these phases must be approved by an institutional review board and the patient must be informed of the risks of the study and sign an informed consent document. Once adequate clinical data are collected and analyzed, the information

APA, Harvard, Vancouver, ISO, and other styles

5

Barreto, Jason N., Kristen B. McCullough, Lauren L. Ice, and Judith A. Smith. "Antineoplastic Agents and the Associated Myelosuppressive Effects." Journal of Pharmacy Practice 27, no. 5 (2014): 440–46. http://dx.doi.org/10.1177/0897190014546108.

Full text

Abstract:

Bone marrow is a complex organ responsible for the regulation of hematopoietic cell distribution throughout the human body. Patients receiving antineoplastic agents as a therapeutic intervention for hematologic malignancy often experience varying degrees of myelotoxicity. Antineoplastic agents cause hypocellularity in marrow resulting in a reduction in hematopoietic tissue activity and a corresponding decline in cell production. Quantifying the adverse effects on hematopoiesis is based on the properties of a single agent, the use of individual drugs within a combination chemotherapy regimen, a

APA, Harvard, Vancouver, ISO, and other styles

6

Adams, Val R. "Evolving role of antineoplastic agents in colorectal cancer." American Journal of Health-System Pharmacy 63, no. 9_Supplement_2 (2006): S4—S11. http://dx.doi.org/10.2146/ajhp060112.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Syrigou, Ekaterini, Nektaria Makrilia, Ioanna Koti, Muhammad W. Saif, and Kostas N. Syrigos. "Hypersensitivity reactions to antineoplastic agents: an overview." Anti-Cancer Drugs 20, no. 1 (2009): 1–6. http://dx.doi.org/10.1097/cad.0b013e32831961b3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Waddell, J. Aubrey, and Dominic A. Solimando. "Irinotecan and Carboplatin (IC) Regimen for Lung Cancer." Hospital Pharmacy 44, no. 9 (2009): 740–45. http://dx.doi.org/10.1310/hpj4409-740.

Full text

Abstract:

The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

9

Lee, Jessica N., J. Aubrey Waddell, and A. Solimando Dominic. "Gemcitabine and Erlotinib (GE) Regimen for Pancreatic Cancer." Hospital Pharmacy 47, no. 1 (2012): 19–23. http://dx.doi.org/10.1310/hpj4701-19.

Full text

Abstract:

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

10

Yang, Jessie, Dominic A. Solimando, and J. Aubrey Waddell. "Docetaxel and Cisplatin Regimen for Non-Small-Cell Lung Cancer." Hospital Pharmacy 48, no. 7 (2013): 550–57. http://dx.doi.org/10.1310/hpj4807-550.

Full text

Abstract:

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

11

Solimando, Dominic A., Kajal Patel, and J. Aubrey Waddell. "Cisplatin and Pemetrexed for Lung Cancer and Pleural Mesothelioma." Hospital Pharmacy 43, no. 10 (2008): 800–805. http://dx.doi.org/10.1310/hpj4310-800.

Full text

Abstract:

The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy and the agents, both commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

12

Rutledge, Matthew R., J. Aubrey Waddell, and Dominic A. Solimando. "Carboplatin (Renally Dosed) and Etoposide Regimen for Small-Cell Lung Cancer." Hospital Pharmacy 48, no. 4 (2013): 274–79. http://dx.doi.org/10.1310/hpj4804-274.

Full text

Abstract:

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

13

Solimando, Dominic A., and J. Aubrey Waddell. "Gemcitabine and Capecitabine (GemCap) Regimen for Solid Tumors." Hospital Pharmacy 44, no. 4 (2009): 303–9. http://dx.doi.org/10.1310/hpj4404-303.

Full text

Abstract:

The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

14

Waddell, J. Aubrey, and Dominic A. Solimando. "Degarelix Plerixafor." Hospital Pharmacy 44, no. 5 (2009): 386–89. http://dx.doi.org/10.1310/hpj4405-386.

Full text

Abstract:

The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

15

Solimando, Dominic A., and J. Aubrey Waddell. "BEACOPP(baseline) Regimen for Hodgkin Lymphoma." Hospital Pharmacy 44, no. 8 (2009): 662–69. http://dx.doi.org/10.1310/hpj4408-662.

Full text

Abstract:

The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

16

Solimando, Dominic A., and J. Aubrey Waddell. "BEACOPP(escalated) Regimen for Hodgkin Lymphoma." Hospital Pharmacy 44, no. 10 (2009): 858–65. http://dx.doi.org/10.1310/hpj4410-858.

Full text

Abstract:

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

17

Erin, K. Morrison, J. Aubrey Waddell, and A. Solimando Dominic. "Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Regimen for Multiple Myeloma." Hospital Pharmacy 46, no. 11 (2011): 839–47. http://dx.doi.org/10.1310/hpj4611-839.

Full text

Abstract:

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

18

Lee, Jessica N., Dominic A. Solimando, and J. Aubrey Waddell. "Drug Monographs: Ziv-aflibercept and Vincristine Sulfate Liposome." Hospital Pharmacy 48, no. 1 (2013): 14–22. http://dx.doi.org/10.1310/hpj4801-14.

Full text

Abstract:

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

19

Solimando, Dominic A., and J. Aubrey Waddell. "Pentostatin, Cyclophosphamide and Rituximab (PCR) Regimen." Hospital Pharmacy 51, no. 11 (2016): 888–93. http://dx.doi.org/10.1310/hpj5111-888.

Full text

Abstract:

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

20

Punke, Alexandra P., J. Aubrey Waddell, and Dominic A. Solimando. "Lenalidomide, Bortezomib, and Dexamethasone (RVD) Regimen for Multiple Myeloma." Hospital Pharmacy 52, no. 1 (2017): 27–32. http://dx.doi.org/10.1310/hpj5201-27.

Full text

Abstract:

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

21

Solimando, Dominic A., and J. Aubrey Waddell. "Procarbazine, Lomustine, and Vincristine (PCV) Regimen for Central Nervous System Tumors." Hospital Pharmacy 52, no. 2 (2017): 98–104. http://dx.doi.org/10.1310/hpj5202-98.

Full text

Abstract:

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

22

Barnett, A. Kacee, J. Aubrey Waddell, and Dominic A. Solimando. "Idelalisib and Rituximab Regimen." Hospital Pharmacy 52, no. 3 (2017): 187–90. http://dx.doi.org/10.1310/hpj5203-187.

Full text

Abstract:

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.

APA, Harvard, Vancouver, ISO, and other styles

23

Schöndorf, Thomas, Rainer Neumann, Carolin Benz, et al. "Antineoplastic agents induce mdr1-gene expression in ovarian cancer cell lines." Anti-Cancer Drugs 12, no. 8 (2001): A10. http://dx.doi.org/10.1097/00001813-200109000-00029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Kawakami, Masanori, Xi Liu, and Ethan Dmitrovsky. "New Cell Cycle Inhibitors Target Aneuploidy in Cancer Therapy." Annual Review of Pharmacology and Toxicology 59, no. 1 (2019): 361–77. http://dx.doi.org/10.1146/annurev-pharmtox-010818-021649.

Full text

Abstract:

Aneuploidy is a hallmark of cancer. Defects in chromosome segregation result in aneuploidy. Multiple pathways are engaged in this process, including errors in kinetochore-microtubule attachments, supernumerary centrosomes, spindle assembly checkpoint (SAC) defects, and chromosome cohesion defects. Although aneuploidy provides an adaptation and proliferative advantage in affected cells, excessive aneuploidy beyond a critical level can be lethal to cancer cells. Given this, enhanced chromosome missegregation is hypothesized to limit survival of aneuploid cancer cells, especially when compared to

APA, Harvard, Vancouver, ISO, and other styles

25

Siragusa, Sergio. "Low Molecular Weight Heparins as Antineoplastic Agents." Recent Patents on Anti-Cancer Drug Discovery 3, no. 3 (2008): 159–61. http://dx.doi.org/10.2174/157489208786242287.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Pettit, George R., Noeleen Melody, and Jean-Charles Chapuis. "Antineoplastic Agents. 603. Quinstatins: Exceptional Cancer Cell Growth Inhibitors." Journal of Natural Products 80, no. 3 (2017): 692–98. http://dx.doi.org/10.1021/acs.jnatprod.6b01006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Mescheryakov, A. A., E. V. Lubennikova, and M. E. Abramov. "Ixabepilone: new perspectives for its use in breast cancer." Medical Council, no. 19 (November 11, 2018): 62–66. http://dx.doi.org/10.21518/2079-701x-2018-19-62-66.

Full text

Abstract:

Despite significant advances in recent years, the drug therapy for breast cancer (BC) is still based on chemotherapy. The introduction of new effective cytostatic agents with a favorable toxicity profile is likely to remain an urgent objective for modern pharmacology in oncology. Ixabepilone, first in a new class of antineoplastic agents, the epothilones, has demonstrated high efficacy in the treatment of breast cancer both in its early stages and in patients, who have received 2 or more lines of chemotherapy. The article discusses the results of major studies, as well as the last meta-analysi

APA, Harvard, Vancouver, ISO, and other styles

28

Haque, Ashanul, Md Ataur Rahman, Md Serajul Haque Faizi, and Muhammad S. Khan. "Next Generation Antineoplastic Agents: A Review on Structurally Modified Vinblastine (VBL) Analogues." Current Medicinal Chemistry 25, no. 14 (2018): 1650–62. http://dx.doi.org/10.2174/0929867324666170502123639.

Full text

Abstract:

Background: Throughout the history of human civilizations, cancer has been a major health problem. Despite the advancements made by modern medical sciences, complete treatment or removal of cancerous cells is still a challenging task. Vinblastine, an alkaloid obtained from Catharanthus roseus (L.) G. Don is one of the prominent antineoplastic agents that is being clinically used. To improve the biological potential and reduce sideeffects of this structurally complex molecule, several related analogues have been reported. The present article reviews recently reported structurally modified vinbl

APA, Harvard, Vancouver, ISO, and other styles

29

Theocharis, S., A. Margeli, and G. Kouraklis. "Peroxisome Proliferator Activated Receptor-Gamma Ligands as Potent Antineoplastic Agents." Current Medicinal Chemistry-Anti-Cancer Agents 3, no. 3 (2003): 239–51. http://dx.doi.org/10.2174/1568011033482431.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Pettit, George R., Venugopal J. R. V. Mukku, Gordon Cragg, et al. "Antineoplastic Agents. 558.Ampelocissussp. Cancer Cell Growth Inhibitory Constituents(1)." Journal of Natural Products 71, no. 1 (2008): 130–33. http://dx.doi.org/10.1021/np068050q.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Moussavian, Parvaneh A., Dominic A. Solimando, and J. Aubrey Waddell. "Ifosfamide, Carboplatin, and Etoposide (ICE) for Metastatic Soft Tissue Sarcoma." Hospital Pharmacy 43, no. 11 (2008): 878–82. http://dx.doi.org/10.1310/hpj4311-878.

Full text

Abstract:

The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy and the agents, both commercially available and investigational, used to treat malignant diseases. The views expressed in this article are those of the author(s) and do not reflect the official policy of the Department of the Army, the Department of Defense, or the United States Government.

APA, Harvard, Vancouver, ISO, and other styles

32

Sainis, Ioannis, Katerina Vareli, Vasilios Karavasilis, and Evangelos Briasoulis. "PPAR: The Portrait of a Target Ally to Cancer Chemopreventive Agents." PPAR Research 2008 (2008): 1–10. http://dx.doi.org/10.1155/2008/436489.

Full text

Abstract:

Peroxisome proliferator-activated receptor-gamma (PPAR), one of three ligand-activated transcription factors named PPAR, has been identified as a molecular target for cancer chemopreventive agents. PPAR was initially understood as a regulator of adipocyte differentiation and glucose homeostasis while later on, it became evident that it is also involved in cell differentiation, apoptosis, and angiogenesis, biological processes which are deregulated in cancer. It is now established that PPAR ligands can induce cell differentiation and yield early antineoplastic effects in several tumor types. Mo

APA, Harvard, Vancouver, ISO, and other styles

33

Rompelman, Florentine MV, Adrianus AJ Smit, Eric JF Franssen, and Mirjam Crul. "Drug–drug interactions of cytostatics with regular medicines in lung cancer patients." Journal of Oncology Pharmacy Practice 23, no. 7 (2016): 483–90. http://dx.doi.org/10.1177/1078155216664200.

Full text

Abstract:

Background Lung cancer patients have a high risk for drug–drug interactions, as they use numerous types of concomitant medicines including antineoplastic agents, cancer treatment co-medication, and medicines aimed at several types of comorbidities. Objective The primary objective of this study is to determine the incidence and the clinical relevance of the drug–drug interactions between antineoplastic agents and regular medication used by lung cancer patients. Secondary objectives are (i) to determine the effectiveness of the medication review by the hospital pharmacists concerned, (ii) to est

APA, Harvard, Vancouver, ISO, and other styles

34

Pettit, George R., Michael S. Hoard, Dennis L. Doubek, et al. "Antineoplastic agents 338. The cancer cell growth inhibitory. Constituents of Terminalia arjuna (Combretaceae)." Journal of Ethnopharmacology 53, no. 2 (1996): 57–63. http://dx.doi.org/10.1016/s0378-8741(96)01421-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Maghsoodnia, Maziar, Walter M. Holleran, and Michael W. DeGregorio. "Estrogen Priming in Advanced Breast Cancer." Drug Intelligence & Clinical Pharmacy 22, no. 9 (1988): 672–75. http://dx.doi.org/10.1177/106002808802200903.

Full text

Abstract:

The successful treatment of advanced breast cancer has reached a plateau in recent years. Estrogen priming is a new combination therapy involving estrogens, antiestrogens, and chemotherapy that may result in the improvement of treatment responses. This investigational therapy is designed to synchronize cell cycles with estrogens and antiestrogens in order to enhance the activity of cell cycle-specific anticancer drugs. The pharmacological manipulation of cell growth coupled with appropriate antineoplastic agents could result in a new treatment approach for advanced breast cancer. The rationale

APA, Harvard, Vancouver, ISO, and other styles

36

Markman, Maurie. "Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies." Trends in Pharmacological Sciences 29, no. 10 (2008): 515–19. http://dx.doi.org/10.1016/j.tips.2008.07.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Mayer, Seth A., Dominic A. Solimando, and J. Aubrey Waddell. "Cancer Chemotherapy Update: Bevacizumab, Etoposide, and Cisplatin Regimen for Refractory Brain Metastases." Hospital Pharmacy 52, no. 6 (2017): 394–99. http://dx.doi.org/10.1177/0018578717717622.

Full text

Abstract:

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc, 4201 Wilson Blvd #110-545, Arlington, VA 22203, email: OncRxSvc@comcast.net ; or J. Aubrey Waddell, Professor, University of

APA, Harvard, Vancouver, ISO, and other styles

38

Makrilia, Nektaria, Ekaterini Syrigou, Ioannis Kaklamanos, Leonidas Manolopoulos, and Muhammad Wasif Saif. "Hypersensitivity Reactions Associated with Platinum Antineoplastic Agents: A Systematic Review." Metal-Based Drugs 2010 (September 20, 2010): 1–11. http://dx.doi.org/10.1155/2010/207084.

Full text

Abstract:

Platinum-containing chemotherapy agents (cisplatin, carboplatin, oxaliplatin) have been approved in the first-line setting of numerous malignancies, such as ovarian, bladder, head and neck, colorectal, and lung cancer. Their extensive use over the last decade has led to a significant increase in the incidence of hypersensitivity reactions, which are defined as unforeseen reactions whose signs and symptoms cannot be explained by the known toxicity of these drugs. Skin rash, flushing, abdominal cramping, itchy palms, and back pain are common symptoms. Cardiovascular and respiratory complications

APA, Harvard, Vancouver, ISO, and other styles

39

Sobottka, Stephan B., and Martin R. Berger. "Assessment of antineoplastic agents by MTT assay: partial underestimation of antiproliferative properties." Cancer Chemotherapy and Pharmacology 30, no. 5 (1992): 385–93. http://dx.doi.org/10.1007/bf00689967.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Bennani-Baïti, M. Idriss, Christiane Lafarge-Frayssinet, Jean Herscovici, et al. "Potential antineoplastic activity of keto-C-glycosides —a new family of cytostatic agents." Anti-Cancer Drugs 3, no. 4 (1992): 351–58. http://dx.doi.org/10.1097/00001813-199208000-00006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Brown, Erika N., and Jon D. Herrington. "Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment." Journal of Pharmacy Practice 21, no. 2 (2008): 126–37. http://dx.doi.org/10.1177/0897190008315057.

Full text

Abstract:

Venous thromboembolism is a common complication that develops in approximately 20% of patients with cancer. Presence of tumor and other risk factors, such as inflammation, surgery, obesity, and medications, have the potential to alter the intravascular coagulation homeostasis and lead to thrombosis. Although malignancy may predispose patients to venous thromboembolism, many chemotherapy agents also increase the risk. In this article, some of the agents tamoxifen, asparaginase, fluorouracil, thalidomide, lenalidomide, bevacizumab, and hematopoietic growth factors are discussed. Many patients wi

APA, Harvard, Vancouver, ISO, and other styles

42

Demir, Yeliz, Cüneyt Türkeş, and Şükrü Beydemir. "Molecular Docking Studies and Inhibition Properties of Some Antineoplastic Agents against Paraoxonase-I." Anti-Cancer Agents in Medicinal Chemistry 20, no. 7 (2020): 887–96. http://dx.doi.org/10.2174/1871520620666200218110645.

Full text

Abstract:

Background: Currently, most of the drugs used in clinical applications show their pharmacological influences by inhibiting or activating enzymes. Therefore, enzyme inhibitors have an essential place in the drug design for many diseases. Objective: The current study aimed to contribute to this growing drug design field (i.e., medicine discovery and development) by analyzing enzyme-drug interactions. Methods: For this reason, Paraoxonase-I (PON1) enzyme was purified from fresh human serum by using rapid chromatographic techniques. Additionally, the inhibition effects of some antineoplastic agent

APA, Harvard, Vancouver, ISO, and other styles

43

Koren, Gideon, Kim Beatty, Arnold Seto, Thomas R. Einarson, and Michael Lishner. "The Effects of Impaired Liver Function on the Elimination of Antineoplastic Agents." Annals of Pharmacotherapy 26, no. 3 (1992): 363–71. http://dx.doi.org/10.1177/106002809202600311.

Full text

Abstract:

OBJECTIVE: To critically review available data on the disposition of cancer chemotherapy in patients with hepatic dysfunction, and to derive at dose recommendation. DATA SOURCES: All published studies in English. STUDY SELECTION: Both human and animal studies. DATA SYNTHESIS: The available studies were sequentially qualitatively described and critically discussed. CONCLUSIONS: The liver is responsible for the metabolism and elimination of many anticancer agents. Their accumulation during hepatic insufficiency may expose the patient to increased risk of drug toxicity. A variety of clinical meth

APA, Harvard, Vancouver, ISO, and other styles

44

Mealey, Katrina L., Rola Barhoumi, Robert C. Burghardt, Stephen Safe, and Deborah T. Kochevar. "Doxycycline Induces Expression of P Glycoprotein in MCF-7 Breast Carcinoma Cells." Antimicrobial Agents and Chemotherapy 46, no. 3 (2002): 755–61. http://dx.doi.org/10.1128/aac.46.3.755-761.2002.

Full text

Abstract:

ABSTRACT P-glycoprotein (P-gp) overexpression by tumor cells imparts resistance to multiple antineoplastic chemotherapeutic agents (multiple drug resistance). Treatment of tumor cells with chemotherapeutic agents such as anthracyclines, epipodophyllotoxins, and Vinca alkaloids results in induction of P-gp expression. This study was performed to determine if clinically relevant antimicrobial drugs (i.e., drugs that are used to treat bacterial infections in cancer patients) other than antineoplastic agents can induce expression of P-gp in MCF-7 breast carcinoma cells. Expression of P-gp and MDR1

APA, Harvard, Vancouver, ISO, and other styles

45

Botana, L. M., E. Arnaez, M. R. Vieytes, et al. "Non-immunological release of histamine from rat mast cells elicited by antineoplastic agents." Cancer Chemotherapy and Pharmacology 29, no. 6 (1992): 495–98. http://dx.doi.org/10.1007/bf00684855.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Ralph, Stephen John. "Arsenic-Based Antineoplastic Drugs and Their Mechanisms of Action." Metal-Based Drugs 2008 (April 9, 2008): 1–13. http://dx.doi.org/10.1155/2008/260146.

Full text

Abstract:

Arsenic-based compounds have become accepted agents for cancer therapy providing high rates of remission of some cancers such as acute promyelocytic leukemia (APL). The mechanisms by which arsenic-containing compounds kill cells and reasons for selective killing of only certain types of cancer cells such as APLs have recently been delineated. This knowledge was gained in parallel with increasing understanding and awareness of the importance of intracellular redox systems and regulation of the production of reactive oxygen species (ROS) by controlling mitochondrial function. Many of the targets

APA, Harvard, Vancouver, ISO, and other styles

47

Shakya, Bhushan, and Paras Nath Yadav. "Thiosemicarbazones as Potent Anticancer Agents and their Modes of Action." Mini-Reviews in Medicinal Chemistry 20, no. 8 (2020): 638–61. http://dx.doi.org/10.2174/1389557519666191029130310.

Full text

Abstract:

: Thiosemicarbazones (TSCs) are a class of Schiff bases usually obtained by the condensation of thiosemicarbazide with a suitable aldehyde or ketone. TSCs have been the focus of chemists and biologists due to their wide range of pharmacological effects. One of the promising areas in which these excellent metal chelators are being developed is their use against cancer. TSCs have a wide clinical antitumor spectrum with efficacy in various tumor types such as leukemia, pancreatic cancer, breast cancer, non-small cell lung cancer, cervical cancer, prostate cancer and bladder cancer. To obtain bett

APA, Harvard, Vancouver, ISO, and other styles

48

Fawzy, Nehmedo G., Siva S. Panda, Walid Fayad, May A. El-Manawaty, Aladdin M. Srour, and Adel S. Girgis. "Novel Curcumin Inspired Antineoplastic 1-Sulfonyl-4-Piperidones: Design, Synthesis and Molecular Modeling Studies." Anti-Cancer Agents in Medicinal Chemistry 19, no. 8 (2019): 1069–78. http://dx.doi.org/10.2174/1871520619666190408131639.

Full text

Abstract:

Background: Curcumin is a well-known example of plant origin exhibiting promising diverse biological properties such as, anti-inflammatory and antitumor as well as poor pharmacokinetic/pharmacodynamic properties. This is why effective agents based on its chemical scaffold were explored. Methods: A set of 3,5-bis(ylidene)-1-(alkylsulfonyl)piperidin-4-ones were synthesized in excellent yield (80- 96%) through dehydrohalogenation reaction of 3,5-bis(ylidene)-4-piperidinones with the corresponding alkane sulfonyl chloride in the presence of triethylamine. Antiproliferative properties of the synthe

APA, Harvard, Vancouver, ISO, and other styles

49

Vickers, Philip P., Robert B. Dixon, and Kenneth H. Cowan. "A pleiotropic response associated with resistance of breast cancer cells to antineoplastic drugs and hormonal agents." Trends in Pharmacological Sciences 9, no. 12 (1988): 443–45. http://dx.doi.org/10.1016/0165-6147(88)90135-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Rodgers, Kathleen E., Wefki Girgis, and Gere S. diZerega. "Effect of tolmetin sodium dihydrate on adhesion formation by intraperitoneal administration of antineoplastic agents." Cancer Chemotherapy and Pharmacology 29, no. 3 (1992): 248–51. http://dx.doi.org/10.1007/bf00686260.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!